You can now read 5 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

Mass. Movers

Celldex Therapeutics rebounds on rating

Continue reading below

Needham biotech Celldex Therapeutics Inc. rebounded a day after it reported a loss for 2012 and for the fourth quarter. Celldex reported a net loss of $16.8 million, or 27 cents per share, for the quarter, compared to loss of $12.7 million, or 29 cents, in 2011. For the twelve months, Celldex reported a net loss of $59.1 million, or $1.02 per share, compared to a loss of $44.8 million, or $1.13, last year. Friday’s jump came after analysts at Leerink Swann initiated coverage for Celldex with a rating of outperform, setting a price of $18.

Loading comments...
Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
Please enter a valid email will never post anything without asking.
Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of